The design and action mechanism of the chimeric peptide Pal-DMPOP dual-targeting the immune checkpoints CD47/SIRPα and PD-1/PD-L1. (IMAGE)

Science China Press

The design and action mechanism of the chimeric peptide Pal-DMPOP dual-targeting the immune checkpoints CD47/SIRPα and PD-1/PD-L1.

Caption

The peptide Pal-DMPOP consists a peptide inhibitor of CD47/SIRPα, a D-peptide inhibitor of PD-1/PD-L1, and a palmitic acid tail conjugated at its N-terminal through a PEG4 linker. This design made this peptide resistant to serum proteolysis and accumulated in the tumor tissues. It can block CD47/SIRPα and PD-1/PD-L1 to enhance the phagocytosis of macrophage, and block PD-1/PD-L1 to restore the function of T cell.

Credit

©Science China Press

Usage Restrictions

Use with credit.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.